Chinese herbal medicine Xiayuxue decoction inhibits liver angiogenesis in rats with carbon tetrachloride-induced liver fibrosis

Journal of Chinese Integrative Medicine

Volumn 9, Issue 8, 2011, Pages 878-887

  Du, Jin Xing ^a,b   Liu, Ping ^a,b   Sun, Ming Yu ^a,b   Tao, Qing ^a,b   Zhang, Li Jun ^a,b   Chen, Gao Feng ^a,b   Hu, Yi Yang ^a,b   Liu, Cheng Hai ^a,b   Xu, Lie Ming ^a,b  

^a SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b Shanghai Key Laboratory of Traditional Chinese Clinical Medicine   (China)

Author keywords

Angiogenesis; Carbon tetrachloride; Chinese herbal; Drugs; Liver cirrhosis; Rats

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ANGIOGENESIS INHIBITOR; CARBON TETRACHLORIDE; CD31 ANTIGEN; CELL PROTEIN; CHINESE DRUG; COLLAGEN; COMPLEMENT DECAY ACCELERATING FACTOR; GELATINASE A; GELATINASE B; HERBACEOUS AGENT; OLIVE OIL; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; VON WILLEBRAND FACTOR; XIAYUXUE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIGEN EXPRESSION; ARTICLE; CHINESE MEDICINE; CONTROLLED STUDY; ENZYME ACTIVITY; HERBAL MEDICINE; HISTOPATHOLOGY; LIVER; LIVER CIRRHOSIS; LIVER FATTY DEGENERATION; LIVER FIBROSIS; LIVER INJURY; LIVER PROTECTION; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PROTEIN CONTENT; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; RAT; SURVIVAL RATE; TREATMENT DURATION;

ACTINS; ANIMALS; ANTIGENS, CD31; ANTIGENS, CD55; CARBON TETRACHLORIDE; DRUGS, CHINESE HERBAL; LIVER; LIVER CIRRHOSIS, EXPERIMENTAL; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; NEOVASCULARIZATION, PATHOLOGIC; RATS; RATS, WISTAR; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VON WILLEBRAND FACTOR;

EID: 80051750080     PISSN: 16721977     EISSN: None     Source Type: Journal    
DOI: 10.3736/jcim20110810     Document Type: Article

References (29)

1. Paternostro C, David E, Novo E, Parola M. Hypoxia, angiogenesis and liver fibrogenesis in the progression of chronic liver diseases. World J Gastroenterol. 2010; 16: 281-288.
2. Mejias M, Garci-Pras E, Tiani C, Miquel R, Bosch J, Fernandez M. Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats. Hepatology. 2009; 49: 1245-1256.
3. Llovet JM, Bruix J. Testing molecular therapies in hepatocellular carcinoma: the need for randomized phase II trials. J Clin Oncol. 2009; 27(6): 833-835.
4. Siegel AB, Cohen EI, Ocean A, Lehrer D, Goldenberg A, Knox JJ, Chen H, Clark-Garvey S, Weinberg A, Mandeli J, Christos P, Mazumdar M, Popa E, Brown RS Jr, Rafii S, Schwartz JD. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol. 2008; 26(18): 2992-2998.
5. Li HR, Li XR. Feasibility for inhibiting tumor metastasis with Chinese herbal medicines as angiogenesis inhibitors. J Chin Integr Med. 2007; 5(4): 378-382. Chinese with abstract in English. (Chinese Source). 2007; 5 (4): 378- 382.
6. Mu YP, Liu P, Liu Y, Li FH, Chen GF, Gu HT, Du GL, Wang L, Wang CS. Inhibiting action of Xiayuxue Decoction on hepatic fibrosis at progressive stage in rats and study on the prescription and syndrome. Zhong Yi Za Zhi. 2006; 47(3): 215-218. Chinese with abstract in English. (Chinese Source). 2006; 47(3): 215-218.
7. Du GL, Liu P, Wang L, Wang CS, Long AH, Mu YP. Relationship between traditional medical formulae and syndrome based pharmacological study of Xiayuxue Decoction against porcine serum induced liver fibrosis in rats. Zhongguo Shi Yan Fang Ji Xue Za Zhi. 2007; 13 (6): 30-33. Chinese with abstract in English. (Chinese Source). 2007; 13(6): 30-33.
8. Nakamura T, Akiyoshi H, Saito I, Sato K. Adenovirus- mediated gene expression in the septal cells of cirrhotic rat livers. J Hepatol. 1999; 30(1): 101-106.
9. Lee TY, Wang GJ, Chiu JH, Lin HC. Long-term administration of Salvia Miltiorrhiza ameliorates carbon tetrachloride-induced hepatic fibrosis in rats. J Pharm Pharmacol. 2003; 55(11): 1561-1568.
10. Bussolino F, Mantovani A, Persico G. Molecular mechanisms of blood vessel formation. Trends Biochem Sei. 1997; 22(7): 251-256.
11. Risau W. Mechanisms of angiogenesis. Nature. 1997; 386(6626): 671-674.
12. Song ZJ, Wang JY. Angiogenesis and liver fibrosis. Guo Ji Xiao Hua Bing Za Zhi. 2008; 28(5): 407-409. Chinese with abstract in English. (Chinese Source). 2008; 28(5): 407-409.
13. Nagy P, Laszlo V, Schaff Z. Hepatocarcinogenesis in human liver. Magy Onkol. 2006; 50(2): 107-113.
14. Raskopf E, Vogt A, Sauerbruch T, Schmitz V. siRNA targeting VEGF inhibits hepatocellular carcinoma growth and tumor angiogenesis in vivo. J Hepatol. 2008; 49(6): 977-984.
15. Thorat MA, Mehrotra S, Morimiya A, Badve S. COX- 2 expression does not correlate with microvessel density in breast cancer. Pathobiology. 2009; 76(1): 39-44.
16. Takahara T, Furui K, Funaki J, Nakayama Y, Itoh H, Miyabayashi C, Sato H, Seiki M, Ooshima A, Watanabe A. Increased expression of matrix metalloproteinase-II in experimental liver fibrosis in rats. Hepatology. 1995; 21(3): 787-795.
17. Taura K, De Minicis S, Seki E, Hatano E, Iwaisako K, Österreicher CH, Kodama Y, Miura K, Ikai I, Uemoto S, Brenner DA. Hepatic stellate cells secrete angiopoietin 1 that induces angiogenesis in liver fibrosis. Gastroenterology. 2008; 135(5): 1729-1738.
18. Aleffi S, Petrai I, Bertolani C, Parola M, Colombatto S, Novo E, Vizzutti F, Anania FA, Milani S, Rombouts K, Laffi G, Pinzani M, Marra F. Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells. Hepatology. 2005; 42(6): 1339-1348.
19. Novo E, Cannito S, Zamara E, Valfre di Bonzo L, Caliqiuri A, Crananzola C, Compagnone A, Colombatto S, Marra F, Pinzani M, Parola M. Proangiogenic cytokines as hypoxia-dependent factors stimulating migration of human hepatic stellate cells. Am J Pathol. 2007; 170(6): 1942-1953.
20. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev. 1997; 18(1): 4-25.
21. Otrock ZK, Makarem JA, Samseddine AI. Vascular endothelial growth factor family of ligands and receptors: review. Blood Cells Mol Dis. 2007; 38(3): 258-268.
22. Plouet J, Moro F, Bertagnolli S, Coldeboeuf N, Mazarguil H, Clamens S, Bayard F. Extracellular cleavage of the vascular endothelial growth factor 189-amino acid form by urokinase is required for its mitogenic effect. J BiolChem. 1997; 272(20): 13390-13396.
23. Langer DA, Shab VH. Nitric oxide and portal hypertension: interface of vasoreactivity and angiogenesis. J Hepatol. 2006; 44(1): 209-216.
24. Grunewald M, Avraham I, Dor Y, Bachar-Lustig E, Itin A, Jung S, Chimenti S, Landsman L, Abramovitch R, Keshet E. VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell. 2006; 124(1): 175-189.
25. Lee JS, Semel D, Iredale J, Shah VH. Sinusoidal remodeling and angiogenesis: a new function for the liver-specific pericyte? Heptology. 2007; 45(3): 817-825.
26. Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Hicklin DJ, Wu Y, Yanase K, Namisaki T, Yamazaki M, Tsujinoue H, Imazu H, Masaki T, Fukui H. Vascular endothelial growth factor and receptor interaction is a prerequisite for murine hepatic fibrogenesis. Gut. 2003; 52(9): 1347-1354.
27. Lidington EA, Haskard DO, Mason JC. Induction of decay-accelerating factor by thrombin through a protease- activated receptor 1 and protein kinase C-dependent pathway protects vascular endothelial cells from complement- mediated injury. Blood. 2000; 96(8): 2784-2792.
28. Mason JC, Lidington EA, Yarwood H, Lublin DM, Haskard DO. Induction of endothelial cell decay-accelerating factor by vascular endothelial growth factor: a mechanism for cytoprotection against complement-mediated injury during inflammatory angiogenesis. Arthritis Rheum. 2001; 44(1): 138-150.
29. Mason JC, Yarwood H, Sugars K, Morgan BP, Davies KA, Haskard DO. Induction of decay-accelerating factor by cytokines or the membrane-attack complex protects vascular endothelial cells against complement deposition. Blood. 1999; 94(5): 1673-1682